Imaging software developer Mirada Medical revealed during the American Society for Radiation Oncology (ASTRO) annual meeting that contours drawn using its deep-learning software are mostly indistinguishable from human-drawn contours.
Adapting the classic Turing test, Mirada conducted a blind survey of oncologists and dosimetrists, asking them to identify whether a contour was drawn by a human or a computer. Contours drawn by Mirada's new deep-learning contouring technology were mostly indistinguishable from human-drawn contours and were found to be suitable for treatment planning purposes, according to the company.
